An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breast cancer

Oncology

Volumn 72, Issue 1-2, 2007, Pages 51-57

  Venturini, M ^a,i   Paridaens, R ^b   Rossner, D ^c   Vaslamatzis, M M ^d   Nortier, J W R ^e   Salzberg, M ^f   Rodrigues, H ^g   Bell, R ^h  

^a Medical Oncology Department   (Italy)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d EVANGELISMOS HOSPITAL   (Greece)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

^g PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^h GEELONG HOSPITAL   (Australia)

ⁱ SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

Author keywords

Capecitabine; Expanded access and compassionate use programs; Fluoropyrimidine; Metastatic breast cancer; Monotherapy; Outpatient treatment

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; FLUOROURACIL; TAXANE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEART DISEASE; HUMAN; LABORATORY TEST; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; THROMBOCYTE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 37049007420     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000111094     Document Type: Article

References (17)

1. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-1281.
2. Schüller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B: Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000;45:291-297.
3. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17:485-493.
4. Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, Osterwalder B: Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001;92:1759-1768.
5. Fumoleau P, Largillier R, Clippe C, Dieras V, Orfeuvre H, Lesimple T, Culine S, Audhuy B, Serin D, Cure H, Vuillemin E, Morere JF, Montestruc F, Mouri Z, Namer M: Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline-and taxane-pretreated metastatic breast cancer. Eur J Cancer 2004;40:536-542.
6. Largillier R, Fumoleau P, Clippe C, Dieras V, Orfeuvre H, Lesimple T, Culine S, Audhuy B, Serin D, Bobadilla L: Capecitabine (X) monotherapy after anthracycline and taxane failure in metastatic breast cancer (MBC): long-term survival data (abstract 161P). Ann Oncol 2006;17(suppl 9):ix74.
7. Reichardt P, von Minckwitz G, Thuss-Patience PC, Jonat W, Kölbl H, Jänicke F, Kieback DG, Kuhn W, Schindler AE, Mohrmann S, Kaufmann M, Lück HJ: Multicenter phase II study of oral capecitabine (Xeloda®) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003;14:1227-1233.
8. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenhacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-799.
9. Talbot DC, Moiseyenko V, Van Belle S, O'Reilly SM, Alba Conejo E, Ackland S, Eisenberg P, Melnychuk D, Pienkowski T, Burger HU, Laws S, Osterwalder B: Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002;86:1367-1372.
10. Mavroudis D, Ardavanis A, Boukovinas I, Varthalitis I, Syrigos K, Potamianou A, Kouroussis C, Georgoulias V: A multicenter randomized study comparing vinorelbine plus gemcitabine versus capecitabine monotherapy as salvage treatment in patients with advanced breast cancer pretreated with taxane and anthracycline chemotherapy: a preliminary report. 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24(suppl 18S):658.
11. O'Shaughnessy JA, Blum J, Moiseyenko V, Jones SE, Miles D, Bell D, Rosso R, Mauriac L, Osterwalder B, Burger HU, Laws S: Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as firstline therapy for advanced/metastatic breast cancer. Ann Oncol 2001;12:1247-1254.
12. Bajetta E, Procopio G, Celio L, Gattinoni L, Della Torre S, Mariani L, Catena L, Ricotta R, Longarini R, Zilembo N, Buzzoni R: Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005;23:2155-2161.
13. Soto C, Torrecillas L, Reyes S, Ramirez M, Perez L, Cervantes G, Gonzalez F, Tellez E, Cortes P, Benitez H: Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): sequential vs. combined therapy results from a MOSG randomized phase III trial. 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24(suppl 18S):570.
14. Stockler MR, Sourjina T, Grimison P, et al: A randomized trial of capecitabine (C) given intermittently (IC) rather than continuously (CC) compared to classical CMF as first-line chemotherapy for advanced breast cancer (ABC). J Clin Oncol 2007;25(18S):1031.
15. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:2812-2823.
16. Leonard RC, Twelves C, Breddy J, Chaturvedi A, Hutcheon A, Salazar R, Cameron D: Capecitabine named-patient programme for patients with advanced breast cancer: the UK experience. Eur J Cancer 2002;38:2020-2024.
17. Pierga JY, Fumoleau P, Brewer Y, Zelek L, Martin D, Turpin FL, Goudier MJ, Gil-Delgado M, Baticle JL, Namer M, Chollet P, Sutherland W, Barats JC; Cooperative Group of the French capecitabine compassionate use program: Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program. Breast Cancer Res Treat 2004;88:117-129.